LEXARIA BIOSCIENCE CORP C/WTS 14/01/2026 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 531.92 K

Revenue: As of FY2025 Q3, the actual value is USD 531.92 K.

EPS: As of FY2025 Q3, the actual value is USD -0.53.

Segment Revenue

• IP Licensing: Revenue for the nine months ended May 31, 2025, was $522,000, compared to $373,990 for the same period in 2024.
• B2B Product: Revenue for the nine months ended May 31, 2025, was $9,923, compared to $5,388 for the same period in 2024.

Operational Metrics

• Net Loss: The net loss for the nine months ended May 31, 2025, was $9,214,206, compared to $3,622,083 for the same period in 2024.
• Operating Expenses: Total operating expenses for the nine months ended May 31, 2025, were $9,721,343, compared to $3,925,522 for the same period in 2024.

Cash Flow

• Operating Cash Flow: Net cash used in operating activities was $7,807,889 for the nine months ended May 31, 2025, compared to $3,067,344 for the same period in 2024.
• Free Cash Flow: The net change in cash for the period was - $1,908,124 for the nine months ended May 31, 2025.

Unique Metrics

• Research and Development: R&D expenses increased significantly to $6,356,637 for the nine months ended May 31, 2025, from $1,393,359 for the same period in 2024, primarily due to clinical trials and drug manufacturing.

Future Outlook and Strategy

• Core Business Focus: Lexaria plans to continue its R&D efforts, particularly in the area of DehydraTECH formulations for GLP-1 drugs and hypertension treatment. The company anticipates increased expenditures in these areas as it progresses with clinical trials.
• Non-Core Business: The company is exploring potential collaborations or strategic partnerships to fund its operations and R&D activities, given the substantial doubt about its ability to continue as a going concern without additional financing.